Eligibility Criteria for Pancreatic Cancer Trials Exclude More Black Patients Than White Patients
Standard eligibility criteria perpetuate racial disparities and are often not medically justifiable, according to researchers.
Pancreatic Cancer
Napabucasin Provides No Added Benefit in Metastatic Pancreatic Cancer
The phase 3 CanStem111P study was terminated early due to futility.
Sex Inequalities Persist in Cancer Clinical Trials
Men nearly always outnumbered women, regardless of trial phase, cancer type, time period, or cancer incidence in the female population.
Rucaparib Maintenance Deemed Safe, Effective for Advanced Pancreatic Cancer
Rucaparib was active in patients with germline BRCA2, germline PALB2, and somatic BRCA2 variants.
Minority Patients Remain Underrepresented in Clinical Trials of Pancreatic Cancer
Non-White and non-Hispanic patients were underrepresented throughout the period studied.
Model More Accurately Predicts Outcomes of Radiotherapy in Cancer Patients
The genomic-adjusted radiation dose (GARD) model predicts outcomes of radiotherapy.
SBRT Plus Pembrolizumab and Trametinib Confers Survival Benefits in Pancreatic Cancer
Stereotactic body radiotherapy plus pembrolizumab and trametinib improved overall and progression-free survival.
Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
Study Supports Maintenance Over Sequential Treatment Strategy in Metastatic Pancreatic Cancer
A sequential treatment strategy was less effective than a maintenance strategy.
Adding Nab-Paclitaxel to Gemcitabine May Improve Overall Survival in Resected Pancreatic Cancer
Nab-paclitaxel was associated with an improvement in long-term overall survival.
- Loading...
Loading...
Next post in Gastrointestinal Cancers
Loading... 
Loading...